Header Ads Widget



Cerebral to stop prescribing most controlled substances 2022

Cerebral will stop giving most controlled substances to new and existing patients, the beleaguered digital mental health company confirmed to insider,

According to an email sent to employees on Monday, Cerebral CEO Kyle Robertson said that the company will discontinue prescriptions of controlled substances such as Adderall and Xanax for new patients from May 20 and for existing patients from October 15.

“This decision was led by our clinical and regulatory teams, and we will release more details on how we do this safely and in the best interest of our patients and physicians,” Cerebral said in a statement. ” insider,

The company will continue to prescribe medications to treat opioid use disorder, as those treatment options can be difficult to use, according to insiderreporting. Cerebral announced it Opioid treatment program in March.

Earlier this month, Cerebral Paused the prescription of controlled substances for new patients and established new safety and quality initiatives, such as greater evaluation capabilities, the hiring of more psychiatrists and psychiatric nurse practitioners, and a system to check its paid social advertisements. Formation of review committee.

why it matters

Cerebral has faced increasing scrutiny over the past several months over its prescribing practices. company is Under investigation by the US Department of Justice for possible violations of the Controlled Substances Act. insider has also reported that the US Drug Enforcement Administration is looking into mental health startups.

Matthew Trube, a former cerebral executive, is sued the company, alleging he was fired after expressing concerns about unethical prescribing practices and patient safety issues.

A Bloomberg Businessweek The investigation from March included interviews with cerebral staff who said they were motivated to write at the expense of patient care.

big trend

As per email seen by insider, is taking steps to halt cerebral prescriptions as patients can now return to hybrid or in-person care. The company introduced prescriptions at the height of the COVID-19 pandemic as the DEA suspended rules that Individual assessment required for controlled substance prescriptions.

The company has defended its prescribed practices in the past. At the American Telemedicine Association Association’s Annual Convention and Expo Earlier this month, Dr. David Moo, Cerebral’s chief medical officer, stuck to his quality standards, but admitted mistakes had been made in areas such as marketing and social media campaigns targeting younger consumers.

Post a Comment